Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.

Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML.

Clin Cancer Res. 2006 Jun 15;12(12):3782-91.

2.

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.

Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR.

J Clin Oncol. 2002 Mar 1;20(5):1182-91.

PMID:
11870159
3.

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.

Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd.

Drug Metab Dispos. 2000 Apr;28(4):423-33.

PMID:
10725311
4.

A randomized trial of minoxidil in chemotherapy-induced alopecia.

Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, Trancik RJ, Bandstra BA, Compton LD.

J Am Acad Dermatol. 1996 Jul;35(1):74-8.

PMID:
8682968
5.

The cardiovascular pharmacology of prostacyclin (PGI2) in the rat.

Weeks JR, Compton LD.

Prostaglandins. 1979 Apr;17(4):501-13.

PMID:
379917

Supplemental Content

Loading ...
Support Center